Literature DB >> 10868474

New insights into the role of COX 2 in inflammation.

D W Gilroy1, P R Colville-Nash.   

Abstract

Cyclo-oxygenase (COX) is responsible for the synthesis of bioactive prostanoids, the inhibition of which serves as the basis for the mode of action of clinically used nonsteroidal anti-inflammatory drugs. While there were suggestions as early as the 1970s that an inducible isoform of COX exists, it was only in the early 1990s that COX 2 was identified, cloned and sequenced. Not surprisingly, this new isoform was expressed at sites of inflammation and reported to contribute to the inflammatory response. Recently, however, evidence is emerging to suggest that COX 2 also has anti-inflammatory properties. In this review, the two faces of COX 2 are examined, with emphasis on its role in regulating inflammatory resolution, including possible mechanisms of action

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868474     DOI: 10.1007/s001090000094

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  25 in total

1.  Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal.

Authors:  Jean-Sébastien Cadieux; Patrick Leclerc; Mireille St-Onge; Andrée-Anne Dussault; Cynthia Laflamme; Serge Picard; Catherine Ledent; Pierre Borgeat; Marc Pouliot
Journal:  J Cell Sci       Date:  2005-03-15       Impact factor: 5.285

2.  Potential anti-inflammatory actions of the elmiric (lipoamino) acids.

Authors:  Sumner H Burstein; Jeffrey K Adams; Heather B Bradshaw; Cristian Fraioli; Ronald G Rossetti; Rebecca A Salmonsen; John W Shaw; J Michael Walker; Robert E Zipkin; Robert B Zurier
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

3.  A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue.

Authors:  Hongfei Yue; Susan A Jansen; Kenneth I Strauss; Michael R Borenstein; Mary F Barbe; Luella J Rossi; Elise Murphy
Journal:  J Pharm Biomed Anal       Date:  2006-11-27       Impact factor: 3.935

4.  The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells.

Authors:  Bin Dong; Fumio Matsumura
Journal:  Mol Endocrinol       Date:  2009-01-15

5.  Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats.

Authors:  Ricardo Valladares; Dhyana Sankar; Nan Li; Emily Williams; Kin-Kwan Lai; Asmaa Sayed Abdelgeliel; Claudio F Gonzalez; Clive H Wasserfall; Joseph Larkin; Desmond Schatz; Mark A Atkinson; Eric W Triplett; Josef Neu; Graciela L Lorca
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

6.  Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice.

Authors:  Ajay J Narasimha; Junji Watanabe; Tomo-o Ishikawa; Saul J Priceman; Lily Wu; Harvey R Herschman; Srinivasa T Reddy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-19       Impact factor: 8.311

Review 7.  Anti-inflammatory properties of lipid oxidation products.

Authors:  Valery N Bochkov; Norbert Leitinger
Journal:  J Mol Med (Berl)       Date:  2003-09-06       Impact factor: 4.599

8.  Induction of heme oxygenase-1 in normal and malignant B lymphocytes by 15-deoxy-Delta(12,14)-prostaglandin J(2) requires Nrf2.

Authors:  Simona Bancos; Carolyn J Baglole; Irfan Rahman; Richard P Phipps
Journal:  Cell Immunol       Date:  2009-12-16       Impact factor: 4.868

Review 9.  Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neurosci Bull       Date:  2018-03-26       Impact factor: 5.203

10.  Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo.

Authors:  G C Ramos; D Fernandes; C T Charão; D G Souza; M M Teixeira; J Assreuy
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.